

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

MTA colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
|---|

It was recognised during the scoping phase that there may be people with cystic fibrosis who could not use the device due to difficulties with manipulating the inhalers for dry powder inhalation. The Committee agreed that this consideration was likely to apply to other methods of administration for treatments, and that this was not an equalities issue that could be addressed by this guidance.

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these? |
|--|

The Committee noted expert statements that cystic fibrosis affects people of White European origin predominately. The Committee agreed that this represented the epidemiology of cystic fibrosis, rather than an equality issue that could be addressed by this guidance.

No further potential equality issues were identified in the submission, or
--

Technology appraisals: Guidance development

Equality impact assessment for the multiple technology appraisal of colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis

Issue date: March 2013

academic report.

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

No further potential equality issues were identified by the Committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

The Committee noted that people with cystic fibrosis who had difficulty manipulating inhalers may be unable to use the device. The Committee understood that the treatment can also be taken using a nebuliser, and agreed that this difficulty may apply to other methods of administration for treatment and was not an equalities issue that could be addressed by this guidance. The Committee concluded that its recommendations would not affect any of the groups whose interests are protected by the legislation and that there was no need to alter or add to its recommendations

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

People may have a disability that prevents them from being able to use the inhaler devices. This may mean that these people would not be able to access this treatment as a dry powder inhalation. However, the Committee understood that it is likely that such groups may also struggle with other methods of administration and agreed that this was not an equalities issue that could be addressed by this guidance. The Committee concluded that its recommendations would not affect any of the groups whose interests are protected by the legislation and that there was no need to alter or add to its

Technology appraisals: Guidance development

Equality impact assessment for the multiple technology appraisal of colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis

Issue date: March 2013

recommendations.

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

7. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

The Committee's considerations of equality issues have been described in section 4.3.18 and in the summary table of the appraisal consultation document.

Approved by Associate Director: Helen Knight

Date: 18/10/2012

Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No additional potential equalities issues were raised during consultation.

2. If the recommendations have changed after consultation, are there

Technology appraisals: Guidance development

Equality impact assessment for the multiple technology appraisal of colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis

Issue date: March 2013

any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

N/A

5. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

FAD Section 4.3.20. The Committee noted a potential equalities issue in that cystic fibrosis mostly affects people of white European origin; however, the Committee recognised that this reflected the epidemiology of cystic fibrosis rather than being an equalities concern. The Committee was also aware that some patients or carers may have difficulty manipulating an inhaler for dry powder inhalation, but noted that the same may apply to other modes of treatment delivery. The Committee concluded that its recommendations would not affect any of the groups whose interests are protected by the

Technology appraisals: Guidance development

Equality impact assessment for the multiple technology appraisal of colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis

Issue date: March 2013

legislation and that there was no need to alter or add to its recommendations.

Approved by Centre or Programme Director: Meindert Boysen

Date: 19/03/2013

Technology appraisals: Guidance development

Equality impact assessment for the multiple technology appraisal of colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis

Issue date: March 2013